Phreesia, Inc.
PHRHealthcareNASDAQHealth Information Services · Last scanned Oct 26, 2026
Scan Results
Daily timeframePhreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The $788.3M market capitalization puts PHR squarely in small-cap range for its industry. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions.
Market Cap
$788.3M
Beta
0.84
P/E (TTM)
74.71
P/E (Fwd)
7.95
EPS (TTM)
$0.17
EPS (Fwd)
$1.60
ROE
3.1%
ROA
2.6%
Cash
$72.9M
Total Debt
$67.9M
Free CF
$68.3M
52W Change
-45.9%
Annual Financials
Cash vs Debt
Where PHR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PHR finished 9.83% above its 150-day moving average ($10.27) and 1.35% above its 200-day moving average ($11.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHR overbought or oversold?
At the October 20, 2026 close, PHR's RSI(14) was 73.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $72.9M in cash and $67.9M in debt, PHR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $68.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 3.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $280.9M (2023) to $480.6M (2026), reflecting a 71% increase over the period.
At over 50x earnings, PHR carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing PHR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.